Dr. Lewis holds prestigious roles as the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSK) and deputy director of the Sloan Kettering Institute in New York. His extensive background embodies a fusion of rigorous scientific inquiry and clinical application, a dual focus that reflects the integral nature of molecular imaging and nuclear medicine in bridging laboratory discoveries with patient-centered therapies. At SNMMI, he aims to leverage this integration by elevating basic science visibility, thereby fostering a symbiotic relationship between foundational research and its clinical deployment.

A central theme in Dr. Lewis’s vision as Vice President-Elect involves enhancing the educational landscape within SNMMI. He asserts that the society must strengthen its role as an educational powerhouse, catering to members across all career stages. By enriching educational content and fostering interdisciplinary collaboration, particularly between basic scientists and clinical investigators, SNMMI can solidify its reputation as an incubator for innovative research methodologies and translational sciences that define tomorrow’s standards of precision medicine.

Dr. Lewis’s commitment extends to nurturing early-career scientists, a group vital for sustaining the momentum of innovation in nuclear medicine. He intends to create novel forums and opportunities tailored specifically for these emerging investigators, emphasizing mentorship, scientific exchange, and active participation in society initiatives. This approach ensures a dynamic generational handoff that preserves and amplifies the society’s mission to push the boundaries of molecular imaging technology and radiopharmaceutical sciences.

Tracing Dr. Lewis’s academic journey underscores the depth of his expertise. He obtained his Bachelor and Master of Science degrees in chemistry from the University of Essex, followed by a doctorate in biochemistry from the University of Kent. His postdoctoral research at Washington University School of Medicine in St. Louis laid the foundation for a distinguished academic trajectory, culminating in his faculty appointment and subsequent transition to MSK, where he has consistently contributed to cutting-edge oncology imaging research.

Within SNMMI, Dr. Lewis’s involvement has been multifaceted. His tenure as secretary and treasurer over the past four years coincided with a period of strategic growth and policy development within the society. He is currently the chair of the SNMMI Task Force on Policy and Review Alignment and the SNMMI Committee on Finance. His membership spans committees encompassing radiopharmaceuticals, awards, and the Clinical Trials Network Research Committee, reflecting his broad influence and leadership across scientific, financial, and clinical dimensions of the society.

Dr. Lewis’s editorial contributions also shape the scientific discourse in nuclear medicine, notably through his role as an associate editor of The Journal of Nuclear Medicine since 2016. This position enables him to guide the dissemination of high-impact research, ensuring rigorous peer review and fostering a scholarly milieu that champions innovative molecular imaging modalities, including positron emission tomography (PET) and theranostics.

His leadership credentials extend internationally, having served as president of the World Molecular Imaging Society (WMIS) and the Society of Radiopharmaceutical Sciences (SRS). These roles highlight his global influence and dedication to the advancement of molecular imaging sciences on a worldwide scale. Such leadership roles complement his recognition as a fellow in several esteemed organizations, including the American Association for the Advancement of Science, the Royal Society of Chemistry, the American Institute for Medical and Biological Engineering, and notably, the National Academy of Inventors.

Dr. Lewis’s scientific achievements have garnered numerous prestigious awards, underscoring his contributions to the nuclear medicine field. These accolades include the Paul C. Aebersold Award, the Michael J. Welch Award, and the Dr. Saul Hertz Lifetime Achievement Award from SNMMI, the ACS Glenn T. Seaborg Award for Nuclear Chemistry, and the WMIS Gold Medal for Lifetime Achievement. Such recognition attests to his innovative research and leadership in developing radiopharmaceuticals and molecular imaging technologies that have clinical impact.

The 2026-27 SNMMI leadership cohort also includes Heather Jacene, MD, as president, and Gary Ulaner, MD, PhD, FSNMMI, FACNM, as president-elect, all of whom share a commitment to advancing scientific discovery and clinical excellence in molecular imaging. The technologist section leadership similarly reflects leadership aimed at advancing clinical practice and technological innovation in nuclear medicine and molecular imaging.

At the core of SNMMI’s mission is the dedication to advancing nuclear medicine, molecular imaging, and theranostics—fields that underpin precision medicine by tailoring diagnostic and therapeutic approaches to individual patient profiles. Under the guidance of leaders like Dr. Lewis, SNMMI is poised to continue driving forward innovations that integrate diagnostic imaging with targeted treatment, enhancing clinical outcomes and expanding the possibilities of personalized medicine.

Dr. Lewis’s appointment heralds a new era at SNMMI, emphasizing synergy between molecular imaging’s scientific foundations and its clinical applications. His strategic focus on education, collaboration, and early-career engagement promises to keep the society at the forefront of medical innovation. As molecular imaging technologies evolve rapidly, the role of guiding institutions and visionary leaders becomes paramount in translating scientific breakthroughs into meaningful clinical benefits.

Driven by a mission to expand the frontiers of molecular imaging and nuclear medicine, Dr. Lewis and the SNMMI will play pivotal roles in orchestrating scientific discourse, policy development, and educational excellence. This trajectory will not only invigorate research communities but also ensure that innovations continue to translate into enhanced patient care paradigms, defining the future landscape of precision oncology and beyond.

Subject of Research: Nuclear Medicine and Molecular Imaging

Article Title: Jason S. Lewis, PhD, FSNMMI, Named Vice President-Elect of the Society of Nuclear Medicine and Molecular Imaging

News Publication Date: 2026 Annual Meeting (May 30-June 2, 2026)

Web References:

• Society of Nuclear Medicine and Molecular Imaging: http://www.snmmi.org/

Image Credits: Courtesy of SNMMI

Keywords: Molecular imaging, Nuclear medicine, Positron emission tomography, Personalized medicine, Radiopharmaceuticals, Theranostics, Precision medicine, Oncology imaging

Dr. Ulaner currently holds the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and serves as a Professor of Radiology and Translational Genomics at the University of Southern California. His multifaceted roles underscore a career dedicated to the integration of molecular imaging technologies and translational research, aligning with the broader goals of personalized medicine and precision oncology. His background exemplifies the merger of academic rigor and clinical application crucial for advancing this rapidly evolving field.

Nuclear medicine, a specialty focused on the use of radioactive substances in diagnosis and therapy, stands at the forefront of precision medicine innovation. The role of the president-elect extends beyond administrative leadership; it includes championing initiatives that fortify research infrastructures, expand educational platforms, and secure funding to nurture the next generation of radiochemistry and nuclear physics professionals. Dr. Ulaner’s vision emphasizes a holistic advancement, where technological innovation dovetails with workforce development and interdisciplinary collaboration.

Dr. Ulaner’s academic foundation was established at Stanford University School of Medicine, where he earned both his MD and PhD in Cancer Biology. His post-doctoral training involved rigorous residencies in Nuclear Medicine and Diagnostic Radiology at the University of Southern California. This robust training has empowered him with a unique perspective that bridges molecular imaging technology, radiopharmaceutical development, and clinical oncology, driving impactful translational research.

Before his current tenure at Hoag Family Cancer Institute, Dr. Ulaner was an Associate Member on a tenure track at Memorial Sloan Kettering Cancer Center—a leading institution in cancer research and treatment. At MSK, he developed significant academic and clinical roles that contributed to the institution’s pioneering work in PET imaging and molecular diagnostics. His professional credentials are further reinforced by certifications from the American Board of Radiology and the American Board of Nuclear Medicine, underscoring his specialized expertise.

Within the SNMMI, Dr. Ulaner has been an active and influential member, occupying vital leadership positions such as director at large on the board of directors, president of the PET Center of Excellence, and chair of the Mars Shot Campaign—a bold initiative aimed at advancing nuclear medicine research. His multifaceted involvement signals his commitment to driving SNMMI’s strategic objectives, including the formulation of standards, educational outreach, and advocacy for nuclear medicine’s value in clinical practice.

His scholarly contributions are substantial, with over 190 journal articles and more than 300 invited presentations. Dr. Ulaner has contributed to seminal guidelines such as SNMMI’s Appropriate Use Criteria for Fluoroestradiol PET, setting standards that influence clinical decision-making globally. His editorial roles and authorship of textbooks like “Fundamentals of Oncologic PET/CT” demonstrate his dedication to disseminating knowledge and fostering an educated workforce proficient in advanced imaging modalities.

The Mars Shot Campaign, under Dr. Ulaner’s leadership, exemplifies a visionary approach to accelerating research and innovation within nuclear medicine. This initiative targets critical translational gaps, funding high-impact projects that aim to develop novel radiopharmaceuticals and imaging technologies with the potential to revolutionize diagnostic accuracy and therapeutic efficacy. Such efforts are crucial in overcoming existing limitations related to imaging biomarkers and personalized treatment monitoring.

Dr. Ulaner’s dedication to education and training extends beyond research innovation. He actively advocates for expanding educational opportunities for nuclear medicine professionals—technologists, clinicians, physicists, and radiochemists—recognizing the interdisciplinary nature of the field. This approach is vital for sustaining a skilled workforce capable of navigating the complexities of molecular imaging and theranostics, transforming patient outcomes in oncology and other disease domains.

Throughout his career, Dr. Ulaner has garnered numerous accolades, including the Susan G. Komen Career Catalyst Award and the Department of Defense Breakthrough Award. His recognition as a Distinguished Investigator by the Academy for Radiology & Biomedical Imaging Research and as a healthcare visionary highlights both his scientific contributions and leadership qualities. Such honors reflect his role as a catalyst for innovation at the interface of cancer biology, imaging science, and clinical oncology.

The SNMMI’s election of new officers alongside Dr. Ulaner—Heather Jacene, MD as president and Jason S. Lewis, PhD as vice president-elect—illustrates a leadership cohort poised to navigate the next frontier of nuclear medicine. Their collective expertise underscores the society’s commitment to fostering cutting-edge research, expanding educational horizons, and enhancing policy frameworks to elevate the role of molecular imaging in modern medicine.

As president-elect, Dr. Ulaner’s agenda will involve steering the SNMMI to harness the full potential of nuclear medicine and molecular imaging technologies. These advancements promise not only to enhance the early detection and characterization of malignancies but also to optimize individualized therapy through theranostics—combining targeted diagnostics with personalized treatment regimens. This paradigm shift aligns closely with contemporary trends aimed at achieving superior patient outcomes through precision health strategies.

The Society of Nuclear Medicine and Molecular Imaging remains at the vanguard of scientific and medical innovation, dedicated to advancing nuclear medicine, molecular imaging, and theranostics worldwide. Dr. Ulaner’s ascension to the role of president-elect represents a pivotal moment in reinforcing the society’s mission. His leadership is expected to invigorate research efforts, expand educational initiatives, and advocate for policies that solidify the critical role of molecular imaging in the healthcare continuum, driving transformative advances for patients globally.

Subject of Research:
Nuclear medicine, molecular imaging, and theranostics with a focus on oncologic PET/CT and translational genomics in cancer care.

Article Title:
Gary Ulaner, MD, PhD, Named President-Elect of the Society of Nuclear Medicine and Molecular Imaging, Heralding New Era in Molecular Imaging and Theranostics

News Publication Date:
June 7, 2026

Web References:
http://www.snmmi.org/

Image Credits:
Courtesy of SNMMI

Keywords:
Molecular imaging, Nuclear medicine, Positron emission tomography (PET), Personalized medicine, Theranostics, Oncology imaging, Radiopharmaceuticals, Translational genomics, SNMMI, PET/CT, Radiochemistry, Molecular diagnostics

The impetus behind these fellowships lies in the rapidly expanding availability of large-scale biological datasets and the increasing necessity for sophisticated computational frameworks to interpret them. Yung S. Lie, PhD, President and CEO of the Damon Runyon Cancer Research Foundation, emphasizes the crucial role of computational expertise in precision medicine, where modeling and data integration are vital for dissecting tumor heterogeneity and treatment responses. The selected fellows epitomize this interdisciplinary approach, bridging “dry” lab quantitative sciences with “wet” lab biological insights to pioneer novel avenues in cancer understanding and intervention.

Among the fellowship recipients is Dr. Minsoo Kim, who focuses on the enigmatic presence of aneuploid cells—cells with abnormal chromosome numbers—in ostensibly healthy breast tissue. Challenging long-held assumptions that normal cells uniformly maintain chromosomal integrity, Dr. Kim’s research investigates these rare aneuploid populations as potential early harbingers of breast cancer. By developing a heterogeneous graph neural network (GNN), his work will jointly model single-cell copy number variations and gene expression data, representing genes, cells, and chromosome segments as distinct nodes. This nuanced modeling approach aims to disentangle gene expression changes driven by chromosomal gains or losses from other transcriptional variations.

Crucially, Dr. Kim intends to extend this computational framework into spatial transcriptomics, which retains the spatial context of gene expression within tissue architecture. This enhancement is designed to illuminate how the microenvironment influences aneuploid cell behavior and interactions, potentially revealing biomarkers for early detection and mechanisms of cancer risk stratification. By applying these analyses to longitudinal breast tissue samples from patients monitored over years, where some subsequently developed cancer, the project aspires to not only refine predictive diagnostics but also offer clinicians tools for earlier, more targeted intervention strategies.

Dr. Sahana Kuthyar’s research addresses a pressing clinical challenge: the elevated risk of severe lung infections in cancer patients undergoing immunosuppressive therapies like chemotherapy and radiation. These treatments, while efficacious against tumors, impair myeloid immune components critical for combating bacterial pathogens, leaving patients vulnerable to conditions such as pneumonia. Moreover, the common clinical practice of providing supplemental oxygen further complicates this risk by altering the pulmonary environment to favor aggressive bacterial proliferation. Dr. Kuthyar’s investigation bridges human and murine models to unravel this complex interplay.

Her computational strategy leverages hierarchical network modeling to integrate gene expression profiles with metabolomic data, applying multi-omics factor analysis for a holistic view of microbial and host immune dynamics under hyperoxic conditions. By cross-validating predictive models between human patients and mouse models, the study aims to iteratively refine understanding of how bacterial adaptation and immune suppression converge to create critical infection vulnerabilities. The insights garnered here may pave the way for predictive diagnostics and novel therapeutic approaches to mitigate life-threatening infections in immunocompromised cancer populations.

Matthew Leventhal, PhD, embarks on a pioneering inquiry into sex chromosome biology within cancer, focusing on the differential roles of active and inactive X chromosomes in females—a subject deeply intertwined with oncogenic potential. Given that females carry two X chromosomes with one subjected to early developmental silencing, mutations impacting the active X chromosome may have outsized consequences on cellular function and tumor progression. Dr. Leventhal’s work centers on developing computational tools capable of resolving the haplotype-specific copy number of chromosomes from bulk whole-genome sequencing data, correcting phasing errors that have historically obscured distinctions between active and inactive X chromosome alterations.

Integrating DNA sequencing with RNA-seq expression data, this methodology will allow for the first pan-cancer analysis of X chromosome dynamics across more than 8,500 tumors spanning 31 cancer types. The goal is to identify recurrent copy number alterations preferentially affecting either the active or inactive X, potentially uncovering novel oncogenic drivers or vulnerabilities previously masked due to analytical limitations. Additionally, determining whether such chromosomal alterations exist in precancerous cells could have transformative implications for early detection and intervention strategies tailored to sex chromosome biology.

The innovations promised by these fellows are testament to the evolving landscape of cancer research, where computational advancements are indispensable to dissecting biological complexity. The utilization of graph neural networks, multi-omics integration, and sophisticated haplotype phasing models exemplifies the next frontier of oncological inquiry, promising heightened precision in diagnosis, prognosis, and treatment. Beyond their individual research agendas, these scientists exemplify the Damon Runyon Foundation’s vision of cultivating interdisciplinary talent equipped to unravel cancer’s multifaceted biology.

Since 1946, the Damon Runyon Cancer Research Foundation has championed early-career investigators, recognizing that the initial years of scientific pursuit are critical for unleashing transformative discoveries. Over $491 million invested and nearly 4,100 funded scientists reflect an enduring commitment to nurturing high-risk, high-reward research. The foundation’s outstanding track record, highlighted by thirteen Nobel laureates among its alumni, underscores its impact on the global cancer research community.

These current fellowships reinforce the need to blur conventional boundaries between computational and biological sciences, reinforcing a paradigm where machine learning algorithms and spatial data are indispensable complements to experimental biology. As the biological sciences grapple with data of unprecedented scale and complexity, the fusion of quantitative expertise and biological insight will catalyze breakthroughs in understanding cancer’s origins, progression, and treatment resistance.

The relevance of this fellow-supported research extends to personalized and precision medicine, where patient-specific molecular data can guide tailored therapeutic regimens. Detecting early aneuploid cell populations, predicting infection risks in susceptible patients, and elucidating sex chromosome influences represent concrete ways in which computational biology is reshaping cancer care. Through these fellowships, the Damon Runyon Foundation equips young scientists with not only resources but also mentorship from leaders in computational and biological cancer research, creating a fertile environment for interdisciplinary innovation.

As these fellows progress, their work is poised to impact fundamental understanding and clinical strategies alike. Whether refining early detection algorithms for breast cancer, unearthing microbial-immune crosstalk in cancer-associated pneumonia, or decoding X chromosome alterations across cancers, these efforts embody a new wave of cancer research empowered by computational sophistication. The field awaits the ripple effects of their discoveries as they translate complex biological data into actionable knowledge with the potential to save lives.

In sum, the 2026 Damon Runyon Quantitative Biology Fellows symbolize a convergence of technology and biology at a pivotal moment in cancer research. Their ambitious projects harness state-of-the-art computational methodologies to tackle profound questions about cancer initiation, progression, and patient vulnerability. Supported by visionary funding and mentorship, these scholars exemplify the future of biomedical research, where multidisciplinary collaboration and quantitative prowess unlock mysteries once deemed impenetrable.

Subject of Research: Computational approaches to cancer biology focusing on early detection, infection risk in immunocompromised patients, and sex chromosome genomics in cancer.

Article Title: Unlocking Cancer’s Complexities: How Computational Pioneers are Shaping the Future of Oncology

News Publication Date: 2026

Web References: http://damonrunyon.org/

Keywords: cancer research, computational biology, machine learning, graph neural networks, spatial transcriptomics, multi-omics analysis, cancer immunology, X chromosome, aneuploidy, precision medicine, early cancer detection, network modeling

Traditional models for bladder cancer, including two-dimensional cell cultures and animal models, have faced persistent limitations due to their inability to faithfully recapitulate the intricate architecture and cellular dynamics of the human bladder. Tumor heterogeneity, interaction with the surrounding healthy tissue, and the biochemical cues within the urothelial niche are often lost or misrepresented outside the human physiological context. Addressing these challenges, the researchers adopted an advanced tissue engineering strategy, cultivating spheroids—three-dimensional aggregates of cancer cells—that retain native tumor features such as hypoxia gradients, cellular heterogeneity, and extracellular matrix deposition.

What sets this model apart is the deliberate integration of these bladder cancer spheroids into an engineered, stratified human urothelium, representing the multilayered epithelial lining that naturally constitutes the inner surface of the bladder. The urothelium is not merely a physical barrier but a dynamic interface involved in signaling, tissue regeneration, and defense mechanisms. By embedding cancer spheroids into this milieu, the model faithfully reproduces critical tumor-stroma interactions, which are vital for understanding tumor progression, invasion, and therapeutic resistance. This spatial architectural mimicry enhances the physiological relevance, enabling researchers to capture the interplay between malignant and non-malignant cell populations.

Construction of the in vitro model involved meticulous optimization of cellular sourcing, growth conditions, and scaffold materials. Primary urothelial cells derived from healthy human donors were cultured to form a differentiated, multilayered epithelium on a biocompatible substrate that mimics the bladder extracellular matrix. Concurrently, bladder cancer cells were cultured to generate spheroids exhibiting representative tumor features. The subsequent co-culture involved seeding the spheroids onto the urothelial model at precise spatial configurations, ensuring optimal integration without compromising the integrity of the healthy epithelium. This process allowed real-time observation of tumor-epithelium crosstalk under controlled laboratory settings.

A key innovation lies in the model’s capability to sustain prolonged viability and functional activity of both tumor spheroids and urothelium, overcoming previous hurdles where co-cultures often suffered rapid deterioration or loss of differentiated features. The researchers employed advanced bioreactors and media formulations to provide dynamic perfusion and nutrient exchange, closely mimicking in vivo physiological conditions. The resulting model demonstrated sustained cell viability, maintenance of differentiation markers in the urothelium, and preservation of tumor cell proliferation and invasion capacity for extended periods, thereby offering a robust platform for longitudinal studies.

Functionally, the integrated model was rigorously validated through histological, molecular, and functional assays. Immunohistochemical staining confirmed the preservation of urothelial differentiation markers such as uroplakins and tight junction proteins, essential for barrier function, alongside expression of tumor-specific markers within the spheroids. Gene expression profiling revealed that key signaling pathways involved in tumor progression and epithelial homeostasis were active in a manner congruent with human disease states. Moreover, live imaging techniques documented dynamic cellular behaviors including tumor cell invasion into healthy tissue layers—a hallmark of cancer aggressiveness.

Perhaps most compellingly, the model displayed remarkable utility in preclinical therapeutic testing. The study assessed the response of bladder cancer spheroids to clinically relevant chemotherapeutic agents and targeted therapies, within the context of the healthy urothelium. This setting unveiled nuanced drug responses that were previously unattainable, including differential sensitivity rooted in tumor-stroma interactions and epithelial barrier effects on drug penetration. Such findings underscore the model’s capacity to predict patient-like responses more accurately than standard cultures, guiding personalized medicine approaches and the development of improved pharmacological regimens.

The innovation extends towards scalability and adaptability, vital for widespread research applications and pharmaceutical development pipelines. The system can be customized by incorporating patient-derived cancer cells, enabling personalized tumor models to test individual responses and resistance mechanisms. Additionally, the framework lends itself to integration with advanced imaging technologies, high-throughput screening, and multi-omics analysis, rendering it a versatile tool for oncology research and drug discovery.

The implications of this study reach far beyond bladder cancer. The modeling strategy exemplifies a blueprint for constructing organ-specific tumor-healthy tissue interfaces, addressing a central challenge in oncology—the need to study cancers within their native microenvironment. This approach could revolutionize how researchers investigate tumor biology, metastasis, immune evasion, and therapeutic resistance across diverse cancer types, fostering innovation in targeted therapies and combination treatments.

Moreover, the study highlights the importance of integrating human-relevant biological complexity into preclinical models to bridge the translational gap between bench and bedside. By faithfully reproducing human bladder architecture and cellular interplay, the model enhances the predictive power of laboratory findings, potentially reducing the high attrition rates seen in clinical trials due to insufficient preclinical efficacy or toxicity data.

In conjunction with emerging technologies such as artificial intelligence and organ-on-chip systems, this in vitro bladder cancer model could evolve further, incorporating immune components, vasculature, and mechanical forces inherent to the urinary bladder environment. Such advancements will deepen our understanding of tumor-host interactions and unveil novel therapeutic targets that may remain concealed in simpler models.

This research underscores the vital role of interdisciplinary collaboration, combining expertise in tissue engineering, cancer biology, molecular pathology, and pharmacology to confront the complexities of cancer modeling. It also sets the stage for future studies aimed at unraveling the multifaceted roles of the urothelium in tumor microenvironment modulation and treatment responses.

In summary, the development of an advanced in vitro bladder cancer model integrating cancer spheroids with a healthy human urothelium embodies a paradigm shift in cancer research. It offers a sophisticated, physiologically relevant platform to investigate tumor biology, evaluate therapeutic strategies, and ultimately improve clinical outcomes for bladder cancer patients. As researchers continue to refine this model and explore its potential, it stands as a beacon of innovation, epitomizing the fusion of biology and engineering to overcome longstanding barriers in cancer science.

Subject of Research: Development of an advanced in vitro bladder cancer model integrating bladder cancer spheroids with healthy human urothelium for improved preclinical therapeutic testing.

Article Title: An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.

Article References:
Murray, B.O., Gao, J., Pasquina-Lemonche, L. et al. An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03476-0

Image Credits: AI Generated

DOI: 02 June 2026

Regenerative healing, the process by which damaged tissues fully restore their original structure and function, stands in stark contrast to fibrotic scarring, where fibrous tissue accumulation results in compromised organ performance. The distinction is not merely cosmetic; scarring often precipitates chronic dysfunction and a cascade of pathological states. Until now, the molecular determinants that decide this critical fate have remained elusive and complex. This new research anchors 4E-BP1 as the key mediator that calibrates protein synthesis pathways, thereby influencing cellular behaviors that dictate healing outcomes.

At the heart of the study lies an intricate analysis of the mechanistic target of rapamycin (mTOR) signaling cascade, a well-known regulator of cell growth, metabolism, and survival. 4E-BP1, a downstream effector in this pathway, governs the translation initiation machinery, thereby modulating protein synthesis rates within cells. The researchers demonstrated through a series of elegant experiments how 4E-BP1’s phosphorylation state effectively acts as a switch or ‘rheostat’—turning cellular machinery toward either regenerative renewal or fibrotic deposition.

Employing cutting-edge molecular biology techniques, the team unveiled that hypo-phosphorylated 4E-BP1 suppresses cap-dependent translation, thereby limiting the synthesis of proteins that promote fibrosis. Conversely, hyper-phosphorylation of 4E-BP1 relieved this suppression, facilitating a profibrotic protein milieu. This dichotomous function illustrates a sophisticated biological control system where 4E-BP1 modulates the translational landscape in a context-dependent manner to ensure optimal tissue response.

Further molecular dissection revealed how 4E-BP1 influences fibroblast activity—the key effector cells in scar formation. Fibroblasts modulate extracellular matrix (ECM) deposition, and their overactivation is a hallmark of fibrosis. The study showed that manipulating 4E-BP1 signaling could recalibrate fibroblast function, attenuating excessive ECM production without hindering normal repair. This selective tuning hints at new therapeutic windows for preventing pathological scarring without impairing necessary tissue sealing and regeneration.

The implications of these findings extend far beyond the laboratory. Chronic fibrotic diseases, such as pulmonary fibrosis, liver cirrhosis, and cardiac fibrosis following myocardial infarction, pose formidable clinical challenges with limited therapeutic options. The molecular insights gained about 4E-BP1 suggest novel intervention points for drug development, targeting translational control mechanisms to shift wound healing outcomes in favor of regeneration rather than fibrosis.

Notably, the researchers employed in vivo models to validate their molecular discoveries, using genetically engineered mice with altered 4E-BP1 expression. These models vividly recapitulated human pathological conditions, where modulated 4E-BP1 activity correlated with improved tissue architecture and function post-injury. The translational potential of these findings is clear, indicating a path toward gene therapy or small-molecule modulators that could revolutionize fibrosis management.

Critically, this study also explores the interplay between 4E-BP1 and inflammatory signaling—a crucial aspect of the healing microenvironment. Excessive or prolonged inflammation is known to skew healing toward fibrosis. The modulation of 4E-BP1 emerged as a nexus point where translational control and immune responses converge, underscoring the multifaceted role of this protein in maintaining tissue homeostasis during repair processes.

Moreover, the work highlights how 4E-BP1 regulation is sensitive to metabolic cues, linking cellular energy status with healing outcomes. Such metabolic integration ensures that tissue repair is not only controlled at the molecular level but also aligned with systemic physiological conditions, an aspect that could explain variability in healing responses among different individuals and disease states.

From a technological perspective, the study harnessed advanced proteomics and transcriptomics to unravel the complex regulatory networks underneath 4E-BP1’s control. By mapping the downstream protein targets whose expression depends on 4E-BP1 modulation, the researchers have opened a treasure trove of candidate molecules for further investigation, offering a panoramic view of the healing landscape at unprecedented resolution.

Looking to the future, this research paves the way for innovative therapeutic strategies that employ fine-tuned modulation of translational repressors like 4E-BP1 to strike a balance between regeneration and scar formation. Such balanced healing responses could markedly improve outcomes for patients suffering from traumatic injuries, surgical wounds, and chronic fibrotic diseases, potentially reducing the global burden of morbidity associated with impaired tissue repair.

In summary, the identification of 4E-BP1 as a molecular rheostat governing the dichotomous nature of wound healing represents a paradigm shift. This molecular balancing act integrates signals from cellular metabolism, inflammatory pathways, and protein synthesis machinery to dictate whether tissues regenerate or scar. The discovery challenges previous dogma that viewed scarring as an unavoidable consequence and instead offers a tangible molecular target for therapeutic innovation.

The translational relevance of this work cannot be overstated. Clinical interventions that can manipulate the phosphorylation state of 4E-BP1 or its interaction with eIF4E could herald a new era in regenerative medicine, offering hope to millions living with the sequelae of fibrosis. This research exemplifies the power of molecular biology to inform and transform therapeutic pathways in complex diseases.

Ultimately, the study underscores a fundamental principle of biology: molecular regulators often function not in binary states but as rheostats, sensitive to a continuum of signals that finely calibrate cellular behavior. The nuanced role of 4E-BP1 in healing offers a compelling model for future research into tissue biology and the molecular choreography of recovery.

The challenge ahead lies in translating these mechanistic insights into effective, safe therapies. Nonetheless, the work of Dou, Li, Lin, and colleagues sets a robust foundation and invigorates the field with a promising framework to decode and manipulate the molecular symphony of healing and fibrosis.

Subject of Research: Molecular mechanisms governing tissue repair, focusing on the role of 4E-BP1 in balancing regenerative healing and fibrotic scarring.

Article Title: 4E-BP1 acts as a molecular rheostat balancing regenerative healing and fibrotic scarring.

Article References:
Dou, H., Li, J., Lin, L. et al. 4E-BP1 acts as a molecular rheostat balancing regenerative healing and fibrotic scarring. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01724-0

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01724-0

Keywords: 4E-BP1, regenerative healing, fibrotic scarring, tissue repair, mTOR signaling, translational control, fibroblast function, fibrosis therapy

The AI model at the heart of this innovation is called Mirai, developed by UC Berkeley data scientist Adam Yala, PhD, who co-led the recent study along with UCSF radiologist Maggie Chung, MD. Unlike traditional diagnostic methods that rely solely on radiologists’ interpretations of mammograms, Mirai taps into machine learning algorithms trained on hundreds of thousands of mammograms linked to known patient cancer outcomes. This extensive training enables the AI to detect subtle, complex patterns invisible to the human eye, thereby assessing cancer risk with an unprecedented degree of accuracy.

Mirai’s predictive capabilities were rigorously evaluated during a clinical application at Zuckerberg San Francisco General Hospital and Trauma Center, where over 4,100 screening mammograms were analyzed. The model identified approximately 12.7% of patients as high-risk, a subset warranting immediate and more intensive follow-up. Crucially, this triage allowed these women to receive a rapid interpretation of their mammogram results immediately after imaging, as well as access to same-day diagnostic mammography or ultrasound. For those requiring tissue biopsies, the process could frequently be completed on the same day, a revolutionary departure from conventional timelines.

Traditionally, women with suspect mammograms endure several weeks of uncertainty before receiving detailed diagnostic evaluations. If cancer is suspected, scheduling a biopsy can extend this delay to more than two months. Mirai’s AI-guided workflow slashes this timeline drastically, condensing diagnostic evaluations to around an hour and reducing biopsy wait times to fewer than ten days. This compression not only alleviates emotional distress but also accelerates treatment initiation when necessary, which can be critical for patient outcomes.

Importantly, Mirai is not designed to supplant radiologists or automate diagnosis in isolation. Rather, it functions as a sophisticated triage instrument, augmenting the clinical decision-making process by highlighting which patients would benefit most from expedited care pathways. This collaborative synergy between AI and human expertise exemplifies how machine learning can enhance physician workflows without compromising clinical judgment.

One of the unique strengths of this study lies in the multi-disciplinary collaboration within the UCSF-UC Berkeley Joint Program in Computational Precision Health. The combined expertise of clinicians, data scientists, and engineers has enabled the fine-tuning of Mirai to optimize patient-level risk stratification without overwhelming clinical resources. The team notably conducted an extensive retrospective analysis of more than 114,000 archival mammograms to calibrate the model’s thresholds, ensuring a practical balance between sensitivity and clinical feasibility.

The broader vision underscored by Chung and Yala is that AI-driven risk assessment can spearhead a more tailored approach to breast cancer screening. Currently, many women adhere to uniform screening intervals regardless of individual cancer risk, resulting in both over-screening and missed opportunities for early intervention. By personalizing screening and diagnostic strategies according to mapped risk profiles, healthcare systems can improve resource allocation and patient outcomes concurrently.

This AI-powered personalization also addresses inequities in breast cancer care by potentially ensuring that those at highest risk receive prompt attention. By triaging based on nuanced risk factors captured within imaging data, Mirai promises to more precisely identify patients who may otherwise slip through the cracks of standardized screening protocols. This prospect of adaptive screening is particularly valuable in resource-limited settings or populations historically underserved by traditional healthcare models.

Furthermore, the rapid diagnostic workflow enabled by Mirai could transform patient experience significantly. The emotional toll of awaiting diagnostic clarity following an abnormal mammogram is well-documented, and condensing this waiting period from weeks to hours offers a profound psychological benefit. Additionally, quicker diagnosis supports timely clinical intervention, which, in many types of breast cancer, correlates with improved prognosis and survival rates.

Technically, Mirai employs deep learning architectures capable of extracting high-dimensional imaging features beyond human perceptibility. These features integrate spatial, textural, and intensity-based imaging biomarkers that correlate with underlying tumor biology and disease progression risks. This holistic image analysis, combined with longitudinal patient data, allows for a dynamic and robust risk model that surpasses traditional radiologic criteria.

While the study’s initial implementation focused on a large urban hospital setting, the researchers envision scalability to diverse clinical environments. The open-source nature of Mirai facilitates replication and customization, advancing widespread adoption. Future work aims to integrate AI risk models seamlessly with electronic health records and clinical workflows to automate triage decisions while maintaining transparency and clinician oversight.

In sum, the deployment of Mirai marks a pivotal step toward precision oncology, where digital tools empower clinicians to deliver faster, smarter, and more compassionate care. By leveraging artificial intelligence not as a replacement but as an intelligent assistant, this approach offers a compelling blueprint for enhancing diagnostic accuracy, reducing patient anxiety, and ultimately saving lives in the battle against breast cancer.

Subject of Research: Artificial intelligence application in breast cancer risk assessment and diagnostic workflow optimization.

Article Title: Not explicitly provided in the content.

News Publication Date: May 19 (Year not specified, presumably 2026 based on article citation).

Web References:

• Study: https://www.nature.com/articles/s41746-026-02743-x
• UCSF Health: https://www.ucsfhealth.org/
• UCSF School of Medicine: https://www.ucsf.edu/

References: Study published in Nature Digital Medicine on May 19.

Image Credits: Not specified.

Keywords: Artificial intelligence, medical diagnosis, mammography, breast cancer, biopsies, personalized medicine, risk assessment, radiography, medical tests, imaging, computational precision health.

This pivotal phase 3 trial evaluated 745 men presenting with prostate cancer confined strictly to the prostate gland, yet characterized by clinical features suggesting a considerable risk for tumor recurrence or metastasis. The participants were enrolled across 51 diverse clinical sites spanning the United States and Puerto Rico, ensuring a comprehensive demographic and clinical diversity. The experimental design involved administering targeted injections of aglatimagene directly into the prostate tissue, combined with the oral administration of valacyclovir, a prodrug whose activation is localized to the prostate microenvironment, concurrently with standard radiation protocols. A control cohort received placebo injections alongside valacyclovir and radiation, establishing a robust comparative framework for evaluating therapeutic efficacy.

Mechanistically, aglatimagene besadenovec employs a genetically engineered adenovirus vector designed to deliver a suicide gene selectively into malignant prostate cells. Once transduced, and upon administration of valacyclovir, the prodrug is metabolically converted into a cytotoxic agent specifically within the infected tumor milieu. This targeted activation disrupts DNA replication selectively within cancerous cells, instigating apoptosis. Additionally, this viral-immunotherapeutic approach promotes a potent, localized immune response, recruiting and activating immune effector cells to target residual tumor foci, a dual modality that underpins its therapeutic promise.

At a median follow-up interval exceeding four years, the trial demonstrated that patients receiving the aglatimagene regimen exhibited a statistically significant extension of disease-free survival compared to the placebo group. Notably, cancer progression, recurrence, or mortality was observed in only 23% of the treated cohort, juxtaposed against 31% in the control arm. Intriguingly, median disease-free survival had not been reached in the investigational group at the time of analysis, underscoring a durable therapeutic effect, whereas the median survival in the placebo group was estimated at approximately 86 months.

Further reinforcing clinical impact, patients treated with aglatimagene displayed superior biochemical control, evidenced by a markedly higher proportion achieving very low prostate-specific antigen (PSA) levels—a biomarker strongly correlated with disease control and prognosis. Substantiating radiologic and pathological findings, post-radiation biopsies assessed at two years revealed a remarkable 80% negative biopsy rate in the aglatimagene cohort, as opposed to 63% in the placebo group, highlighting effective tumor eradication.

Importantly, this augmented therapeutic activity did not correspond with a significant increase in adverse events. The severity profile of side effects remained predominantly mild to moderate with comparable incidence of serious treatment-related toxicity between study arms (8% in the aglatimagene group versus 7% in placebo). Crucially, no treatment-associated mortality was documented, underscoring the favorable safety margin of this viral immunotherapy when combined with radiation.

These findings underscore the mechanism-based rationale behind utilizing a viral vector to introduce suicide genes selectively targeting tumor cells while stimulating anti-tumor immunity, addressing the unmet clinical need for more effective and less toxic prostate cancer therapies. Given that approximately 30% of patients with localized intermediate- to high-risk disease traditionally experience relapse post-curative interventions, aglatimagene besadenovec represents a much-needed advancement capable of altering disease trajectories and improving long-term outcomes.

The study, financially supported in part by the National Institutes of Health and conducted under an FDA Special Protocol Assessment, emphasizes the importance of extensive, regulated clinical evaluation for novel immunotherapies. The promising results reported validate earlier phase data and provide a strong regulatory and clinical foundation for potential approval, paving the way for integration into standard prostate cancer treatment algorithms.

Leading prostate cancer experts, including Theodore DeWeese, M.D., the principal investigator, emphasize that aglatimagene besadenovec could become the first new frontline therapeutic addition for localized prostate cancer in over two decades, reflecting a major step forward in disease management. The viral immunotherapy’s dual action — direct oncolysis via gene-mediated cytotoxicity combined with immunomodulatory effects — represents a sophisticated approach aligned with the evolving landscape of precision oncology.

Long-term follow-up remains critical to fully elucidate whether this treatment combination not only prolongs disease-free intervals but also mitigates the necessity for subsequent salvage therapies, such as androgen deprivation therapy, and ultimately impacts overall survival. Current data provide compelling evidence for incorporating immunovirotherapy into multidisciplinary prostate cancer care, expanding beyond conventional modalities alone.

The research team also highlighted the collaborative efforts of numerous urology and oncology centers, reflecting a concerted national effort to tackle the challenges of prostate cancer recurrence and improve patient quality of life. By selectively harnessing viral vectors to intelligently target tumor biology and harness host immunity, aglatimagene besadenovec represents a beacon of hope for men confronting this disease.

In summary, this multicenter clinical trial convincingly demonstrates that the addition of an adenoviral-based viral immunotherapy to established radiation treatments substantially enhances disease-free survival in men harboring intermediate- and high-risk localized prostate cancer. The investigational agent’s promising efficacy and manageable safety profile could signal a transformative advance in prostate cancer therapeutics, underpinning ongoing investigations aimed at solidifying its role in clinical practice.

Subject of Research: Adenoviral-based viral immunotherapy (aglatimagene besadenovec) in localized prostate cancer

Article Title: Not provided

News Publication Date: June 1, 2023

Web References:

• Johns Hopkins University School of Medicine: https://www.hopkinsmedicine.org/som
• Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel-cancer-center
• Department of Radiation Oncology and Molecular Radiation Sciences: https://www.hopkinsmedicine.org/radiation-oncology
• Brady Urological Institute: https://www.hopkinsmedicine.org/brady-urology-institute
• The Lancet Oncology: https://www.thelancet.com/journals/lanonc/home

References: The multicenter clinical trial publication in The Lancet Oncology, June 1, 2023

Image Credits: Courtesy of the Johns Hopkins University School of Medicine

Keywords: Prostate cancer, viral immunotherapy, aglatimagene besadenovec, adenoviral vector, radiation therapy, disease-free survival, valacyclovir, phase 3 clinical trial, prostate-specific antigen, immune response, targeted gene therapy, cancer recurrence

Breast cancer represents a heterogeneous disease with diverse molecular profiles that influence prognosis and therapeutic responses. Among these, hormone receptor–positive subtypes constitute a significant proportion, with estrogen and progesterone receptor statuses guiding treatment paradigms. Statins, widely prescribed lipid-lowering agents primarily used to manage hypercholesterolemia, have been hypothesized to exert anticancer effects through mechanisms that extend beyond cholesterol regulation, including anti-inflammatory properties, modulation of cell proliferation, and apoptosis enhancement.

The cohort under scrutiny comprised patients with early-stage breast cancer, meticulously characterized by their hormone receptor status. Researchers sought to elucidate whether the timing of statin use—before or after cancer diagnosis—influenced overall survival and breast cancer–specific mortality. Intriguingly, findings indicated that prediagnostic statin use did not confer a survival advantage, suggesting that statins taken prior to tumor detection may not affect the disease trajectory. This outcome challenges some earlier retrospective assertions and underscores the importance of dynamic tumor-microenvironment interactions post diagnosis.

Conversely, postdiagnostic initiation of statin therapy demonstrated a pronounced association with decreased mortality rates, specifically in patients with hormone receptor–positive intrinsic subtypes. This subclass of breast cancer relies significantly on hormone signaling pathways for growth, rendering it susceptible to interventions that may disrupt these pathways. Statins’ biochemical interference in isoprenoid synthesis—a pathway vital for post-translational modification of proteins such as Ras and Rho involved in cell proliferation and metastasis—could underlie these observed survival benefits.

The implications of these results are multifaceted. From a clinical perspective, they advocate for further prospective trials to rigorously evaluate statins as adjunctive agents in breast cancer management, especially considering their established safety profile and widespread availability. Moreover, this study prompts oncologists to reconsider the temporal window during which statin therapy might be optimized to exploit its potential oncologic advantages.

Mechanistically, the study stimulates a closer examination of how statins modulate tumor biology in the context of hormone receptor–positive cancers. Beyond lipid modulation, statins may impede tumor cell cycle progression, reduce inflammatory cytokine production, and enhance immune surveillance. The identification of biomarkers predicting responsiveness to statin therapy could further personalize treatment, maximizing therapeutic efficacy while minimizing unnecessary exposure.

This study also addresses broader epidemiological concerns, particularly the intersection of cardiovascular and oncologic patient care. Given that breast cancer survivors often face heightened cardiovascular risk due to the cardiotoxic effects of some cancer therapies, statins’ dual role in managing dyslipidemia and potentially improving cancer outcomes is especially salient.

Statin pharmacodynamics within the tumor microenvironment necessitate further elucidation. The differential impact of hydrophilic versus lipophilic statins on breast cancer cells, their penetration into mammary tissues, and influence on metabolic reprogramming of cancer cells warrant comprehensive investigation. This differentiation could inform drug selection in future clinical protocols aiming to leverage statins in oncology.

The study’s cohort design, while robust in sample size and longitudinal follow-up, naturally invites calls for randomized controlled trials to definitively establish causality and exclude residual confounding. However, the rigor in adjusting for known confounders, including comorbidities and concurrent therapies, strengthens the validity of the observed associations.

This research also highlights the evolving paradigm of repurposing existing medications for cancer treatment—a field gaining momentum due to the cost-effectiveness and expedited availability of familiar drugs. Statins exemplify this trend, providing a promising avenue for integrating pharmacological agents with established safety records into oncology treatment algorithms.

In light of these insights, future research trajectories might explore synergistic effects of statins combined with endocrine therapies, given the shared targeting of hormone-dependent pathways. Moreover, investigations into the timing and dosage optimization of statins in the oncology setting would be critical to translating these observational findings into actionable clinical guidelines.

Overall, this study catalyzes a nuanced understanding of statin therapy within breast cancer management, emphasizing the importance of treatment timing and molecular subtype in modulating outcomes. As survival plateaus in certain cancer subgroups necessitate innovative approaches, the promise held by statins—a cornerstone of cardiovascular medicine—signals an exciting frontier in cancer therapeutics with the potential to transform patient survival trajectories.

Subject of Research: Impact of statin therapy on survival outcomes in early hormone receptor–positive breast cancer patients.

Article Title: Not specified within provided content.

References: doi:10.1001/jamanetworkopen.2026.16375

Keywords: Breast cancer, Statins, Cohort studies, Hormone receptor–positive subtypes, Mortality rates, Oncology, Hormones, Medical treatments, Medical diagnosis.

Colorectal cancer remains a formidable health challenge worldwide, ranking among the top causes of cancer-related mortality. Despite extensive investigation into cancer cell-intrinsic mechanisms driving CRC, the tumor microenvironment (TME) has emerged as a pivotal player influencing tumor progression, metastasis, and response to therapy. The TME comprises a complex milieu of stromal fibroblasts, immune cells, extracellular matrix components, and signaling molecules that interact dynamically with malignant cells.

The study, spearheaded by Haylee Duval at the Center for Molecular Medicine within the MaineHealth Institute for Research, utilized genetically engineered mouse models to dissect the function of CTHRC1 within the CRC microenvironment. By creating a global knockout of CTHRC1 (Cthrc1 KO), the team systematically compared tumor growth kinetics, immune cell infiltrate profiles, and histological features with those observed in wild-type (WT) mice following subcutaneous inoculation of colorectal cancer cells.

Their findings were remarkable. Tumors developing in Cthrc1 KO mice were consistently smaller and demonstrated regression over time. Most strikingly, survival analysis revealed a profound extension of median survival from 28 days in WT mice to 69 days in those lacking CTHRC1. This enhancement in longevity underscores the tumor-promoting influence of CTHRC1 and suggests potential therapeutic value in targeting this protein.

Immune profiling indicated that CTHRC1 exerts a suppressive effect on anti-tumor immunity. Quantitative analyses showed increased percentages of CD3+ T lymphocytes in both the tumors and spleens of Cthrc1-deficient mice, implying a reactivation of immune surveillance mechanisms. Conversely, levels of myeloid-derived suppressor cells and other immunoregulatory myeloid populations were attenuated. These observations illuminate CTHRC1 as a critical immune checkpoint modulator within the CRC microenvironment, facilitating immune evasion by tumor cells.

Interestingly, the researchers confirmed through rigorous assays that colorectal cancer cells per se did not express detectable CTHRC1. Instead, the protein localized predominantly to stromal fibroblasts and extracellular matrix compartments encasing the tumor mass. This localization highlights the significance of host stromal components in mediating tumor progression, emphasizing that the microenvironment—not merely cancer cells—can orchestrate oncogenic processes.

Histological analyses reinforced these conclusions. Using specialized staining techniques such as Trichrome and Hematoxylin and Eosin (H&E), the investigators revealed striking structural differences between WT and Cthrc1 KO tumors. Tumors from KO mice displayed reduced cellularity and evidence of fibrotic regression, whereas WT tumors maintained dense cellular matrices conducive to aggressive growth. Immunostaining confirmed the presence of CTHRC1 protein exclusively in WT tumor capsules, correlating with the fibrotic and immunosuppressive tumor architecture.

The study also explored vascular characteristics through CD31 immunostaining to assess angiogenesis. Both WT and KO tumors showed presence of blood vessel-like structures; however, the influence of CTHRC1 on vascular remodeling and its potential contribution to tumor nourishment and metastasis remain areas for further investigation.

Mechanistically, the data support a model whereby stromal-derived CTHRC1 modifies the tumor niche to impair effective immune cell infiltration and activation, thereby shielding tumor cells from immune attack. This immunomodulatory effect likely facilitates uninterrupted tumor cell proliferation and survival, underscoring the importance of targeting microenvironmental factors in cancer therapy.

The implications of these findings are far-reaching. By pinpointing stromal CTHRC1 as a pro-tumorigenic factor, the study opens new avenues for therapeutic intervention that extend beyond conventional cancer cell-centric approaches. Inhibiting CTHRC1 function could restore immune competence within tumors, enhance immunotherapy responses, and ultimately improve patient outcomes in colorectal cancer.

Moreover, the demonstration that host-derived CTHRC1—not tumor cell-derived—drives disease progression challenges existing paradigms and emphasizes the necessity for holistic views of cancer biology incorporating both tumor and stromal elements. Future studies focused on the molecular pathways downstream of CTHRC1 signaling may reveal druggable targets within the tumor microenvironment.

In conclusion, the research provides compelling evidence that CTHRC1 is a pivotal modulator of colorectal cancer progression by fostering an immunosuppressive and structurally supportive microenvironment. This protein’s dual role in immune evasion and tumor architecture underscores its potential as a novel biomarker and therapeutic target. As the global burden of colorectal cancer continues to rise, insights into TME regulation such as those presented in this study are vital for developing next-generation treatments.

The authors acknowledge that further clinical validation and development of CTHRC1-targeting agents are necessary steps toward translating these preclinical findings into effective patient-centered therapies. Nevertheless, the study significantly advances understanding of CRC biology and highlights the promise of stromal-targeted interventions in combatting this deadly disease.

Subject of Research: Not applicable

Article Title: Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer

News Publication Date: 20-May-2026

Web References:
https://doi.org/10.18632/oncotarget.28878

Image Credits: Copyright © 2026 Duval et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords: cancer, Cthrc1, CRC, colorectal cancer, subcutaneous tumor model, immune analysis

The Alliance for Clinical Trials in Oncology represents a broad coalition committed to enhancing the scientific community’s understanding of cancer across diverse populations. Within this framework, the Cancer in the Older Adult Committee is pivotal in refining study protocols and interventions that specifically cater to the elderly demographic, so frequently underrepresented in oncology research. Central to the committee’s mission is the evaluation of geriatric assessments, which integrate physical, cognitive, and psychosocial dimensions, and the critical appraisal of treatment toxicities alongside quality of life metrics during clinical trials.

In his co-chair role, Dr. Sedrak will collaborate closely with Dr. Vijaya Raj Bhatt from the University of Nebraska Medical Center, bringing a wealth of clinical and research expertise to direct investigations aimed at improving therapeutic outcomes and supportive care paradigms for older adults facing cancer diagnoses. Their joint vision emphasizes a multidisciplinary approach, recognizing that aging biology profoundly influences cancer progression, treatment tolerance, and survivorship trajectories.

Dr. Sedrak has long championed the imperative to recalibrate cancer research priorities to better include older adults, who constitute the majority of new cancer cases yet remain dramatically underrepresented in clinical trials. He underscores that conventional oncologic studies often fail to capture the heterogeneity of this group, partly because aging entails a constellation of comorbidities, functional limitations, and physiological vulnerabilities that can modify treatment efficacy and side effect profiles.

His scientific contributions extend to elucidating the interplay between cancer therapies and aging biology. Using geriatric oncology frameworks, Dr. Sedrak’s research aims to unravel mechanisms by which cancer treatments may accelerate biological aging or exacerbate age-associated syndromes such as frailty, cognitive decline, and reduced resilience. Understanding these interactions is fundamental to tailoring interventions that not only prolong life but optimize health span—allowing older survivors to live more years free from disability and with preserved independence.

Clinical trials that incorporate comprehensive geriatric assessments are a cornerstone of this shift. These assessments evaluate multiple domains, including functional status, comorbid medical conditions, cognitive function, nutritional status, psychological health, and social factors. By integrating this multidimensional data, researchers can better stratify risk, predict treatment toxicity, and individualize treatment plans in older adults, thereby maximizing therapeutic benefits while minimizing harm.

Another facet of Dr. Sedrak’s work is the rigorous examination of treatment toxicity patterns in the elderly. Age-related declines in organ function and cumulative health burdens can substantially alter pharmacodynamics and pharmacokinetics, influencing how drugs are metabolized and cleared. This necessitates novel dosing strategies and supportive care measures to mitigate adverse effects, maintain quality of life, and sustain patients’ functional capacity throughout the course of treatment.

Quality of life (QoL) research within the aging cancer population is equally imperative. Dr. Sedrak emphasizes that mere survival metrics are insufficient to judge success; rather, patient-reported outcomes related to physical, emotional, and social well-being must be integrated into study endpoints. This holistic perspective aligns treatment goals with patient values, ensuring that longevity does not come at the expense of meaningful, active living.

The committee’s work is further informed by demographic trends. An aging global population means that the proportion of older adults with cancer will continue to rise. Hence, research tailored to this demographic is not simply beneficial but essential to manage future cancer care burdens effectively. The committee advocates for policy changes and funding reallocations to support geriatric oncology research infrastructures and education initiatives.

Dr. Sedrak’s academic role at the David Geffen School of Medicine at UCLA situates him at the nexus of translational research, where clinical insights inform laboratory investigations and vice versa. His interdisciplinary collaborations encompass oncologists, geriatricians, pharmacologists, and biostatisticians, aimed at refining predictive models for toxicity and outcomes in elderly patients. His approach exemplifies precision medicine applied to the unique biology of aging in oncology.

The emphasis on survivorship is transformative. Traditionally, cancer survivorship research concentrated on younger populations; however, Dr. Sedrak advocates for expanding this focus to incorporate age-related functional recovery and mitigation of late effects. His vision challenges the oncology community to redefine success, emphasizing not only longer survival but enhanced functional independence and dignity in older patients.

In summary, Dr. Mina Sedrak’s selection as co-chair heralds a significant advance in addressing the deficits in cancer research for older adults. His leadership and scientific expertise will propel forward the development of clinical trials and care models that are inclusive, comprehensive, and attuned to the complexities of aging biology. Through this work, the oncology field moves closer to achieving equitable, effective, and compassionate care for an aging population facing cancer.

Subject of Research: Geriatric oncology, clinical trials, cancer treatment in older adults, aging biology and cancer survivorship
Article Title: Dr. Mina Sedrak Appointed Co-Chair to Drive Progress in Cancer Research for Older Adults
News Publication Date: Not provided
Web References: https://www.uclahealth.org/providers/mina-sedrak, https://www.uclahealth.org/cancer
Keywords: Cancer, older adults, geriatric assessment, clinical trials, treatment toxicity, quality of life, survivorship, aging populations, oncology research